Hemodynamic effects of ephedra-free weight-loss supplements in humans.

[1]  A. Fugh-Berman,et al.  Citrus aurantium, an Ingredient of Dietary Supplements Marketed for Weight Loss: Current Status of Clinical and Basic Research , 2004, Experimental biology and medicine.

[2]  S. Durning,et al.  Exercise-induced syncope associated with QT prolongation and ephedra-free Xenadrine. , 2004, Mayo Clinic proceedings.

[3]  D. Nykamp,et al.  Possible Association of Acute Lateral-Wall Myocardial Infarction and Bitter Orange Supplement , 2004, The Annals of pharmacotherapy.

[4]  N. Benowitz,et al.  Enhanced Stimulant and Metabolic Effects of Combined Ephedrine and Caffeine , 2004, Clinical pharmacology and therapeutics.

[5]  N. Benowitz,et al.  Determination of ephedra alkaloid and caffeine concentrations in dietary supplements and biological fluids. , 2004, Journal of analytical toxicology.

[6]  P. Shekelle,et al.  Efficacy and Safety of Ephedra and Ephedrine for Weight Loss and Athletic Performance , 2003 .

[7]  A. Leon,et al.  Elusive amines and primary headaches: historical background and prospectives , 2003, Neurological Sciences.

[8]  Paul G Shekelle,et al.  Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. , 2003, JAMA.

[9]  Paul J. Wang,et al.  Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. , 2002, Mayo Clinic proceedings.

[10]  M. Jann,et al.  Seville (sour) Orange Juice: Synephrine Content and Cardiovascular Effects in Normotensive Adults , 2001, Journal of clinical pharmacology.

[11]  N. Benowitz,et al.  Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. , 2001, The New England journal of medicine.

[12]  F. Squadrito,et al.  Antiobesity and cardiovascular toxic effects of Citrus aurantium extracts in the rat: a preliminary report , 1999 .

[13]  T. Perlis,et al.  Effects of Citrus aurantium extract, caffeine, and St. John's Wort on body fat loss, lipid levels, and mood states in overweight healthy adults , 1999 .

[14]  R. Branch,et al.  A pharmacodynamic interaction between caffeine and phenylpropanolamine , 1991, Clinical pharmacology and therapeutics.

[15]  N. Benowitz,et al.  Clinical pharmacology of caffeine. , 1990, Annual review of medicine.

[16]  J. McGrath,et al.  Activities of octopamine and synephrine stereoisomers on α‐adrenoceptors , 1988 .

[17]  J. Hengstmann,et al.  [Pharmacokinetics and metabolism of 3H-synephrine (author's transl)]. , 1978, Arzneimittel-Forschung.